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Abstract
Aims Although loop diuretics are the most commonly used drugs in acute heart failure (AHF) treatment, their short-term and
long-term effects are relatively unknown. The significance of worsening renal function occurrence during intravenous treat-
ment is not clear enough. This trial aims to clarify all these features and contemplate whether continuous infusion is better
than an intermittent strategy in terms of decongestion efficacy, diuretic efficiency, renal function, and long-term prognosis.
Methods and results This is a prospective, multicentre, randomized study that compares continuous infusion to intermittent
infusion and a low vs. high diuretic dose of furosemide in patients with a diagnosis of acute heart failure, BNP ≥ 100 pg/mL,
and specific chest X-ray signs. Randomization criteria have been established at a 1:1 ratio using a computer-generated scheme
of either twice-daily bolus injection or continuous infusion for a time period ranging from 72 to 120 h. The initial dose will be
80 mg/day of intravenous furosemide and, in the case of poor response, will be doubled using an escalation algorithm. A high
diuretic dose is defined as a furosemide daily amount >120 mg/day respectively.
Conclusions Continuous and high dose groups could reveal a more intensive diuresis and a greater decongestion with
respect to intermittent and low dose groups; high dose and poor loop diuretic efficiency should be related to increased
diuretic resistance, renal dysfunction occurrence, and greater congestion status. Poor diuretic response will be associated with
less decongestion and an adverse prognosis.
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Introduction
Acute heart failure (AHF) is characterized by a rapid progres-
sion of signs and symptoms resulting in the necessity of urgent
therapy. Despite its high prevalence, the pathophysiological
mechanisms and treatment options remain poorly defined
and vastly understudied. Loop diuretics are the drugs most
commonly used in the treatment of AHF, but their short-term
and long-term effects are relatively unknown. The administra-
tion of intravenous loop diuretics in patients with heart failure
and congestion typically results in a prompt diuretic effect and
decongestion. Nevertheless, high-quality data supporting the
best modality of administration, the appropriate dosage, and
infusion timing are lacking: It is not clear if continuous infusion
is better than intermittent boluses in terms of worsening renal
function (WRF), urine output, B-type natriuretic peptide (BNP)
reduction, diuretic efficiency (DE), and prognosis. For all of
these reasons, we aim to investigate the effect of the two
different modalities of administration through a step-by-step
algorithm based on the response to diuretic therapy.
Diuretics may be associated with neuro-hormonal activa-
tion, worsening renal insufficiency, electrolyte abnormalities,
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and arrhythmias. Moreover, patients receiving high diuretic
doses had significantly impaired survival rates during follow-
up.1 Recently, the Diuretic strategies in patients with acute
decompensated heart failure (DOSE-AHF) trial has not found
superiority in terms of loop diuretics dosage or administra-
tion modality.2 However, it was found that continuous
infusions at higher doses resulted in a greater incidence of
impaired renal function.
A Cochrane analysis comparing continuous vs. intermittent
infusion showed a better profile of continuous administration
modality in terms of urine output, hospital adverse events,
and length of hospitalization. However, it recommended
larger studies to adequately settle this issue in particular in
patients with preserved left ventricular ejection fraction.3 It
is still unclear what the impact of different types of diuretic
infusion and DE is after discharge in predicting late adverse
events occurrence. Indeed, previous studies in this field are
post hoc analyses and mostly biased by new therapies tested
in AHF.4,5 Finally, the most similar protocol (DOSE) evaluated
a shorter in-hospital and post-discharge outcome (60 days)
with respect to our observational period (180 days).2 For all
of these reasons, we aim to clarify several aspects regarding
renal function, drugs safety, and the best modality of infusion
comparing the two groups (continuous vs. intermittent
infusion). (Table 1) More precisely, we will investigate the
following in-hospital endpoints: creatinine and estimated
glomerular filtration rate (eGFR), mean urine output and
body weight, BNP, and blood urea nitrogen before treatment
and at the end of infusion period as both continuous vs.
intermittent infusion and in low vs. high diuretic dose arms.
The additional in-hospital outcomes assessment includes rate
of WRF, use of hypertonic saline solution and inotropic
agents, evaluation of DE, congestion signs (persistence of
one or more of the following signs: pulmonary rales, periph-
eral oedema, jugular venous distension, hepatomegaly, third
heart sound, and dyspnoea score), and length of hospital stay.
Late outcome endpoints during a 6 month follow-up
period include (i) cardiac death and re-hospitalization for
heart failure; (ii) evaluation of renal function and its potential
relation to adverse events; and (iii) evaluation of post-
discharge outcome with respect to congestion signs at
discharge.
Study design
DIUR-AHF is a prospective, multicentre, randomized study
that compares continuous with intermittent infusion and
low vs. high diuretic dose of furosemide in patients admitted
with a diagnosis of AHF. A previous pilot study design was
planned to anticipate a larger multicentre trial able to
definitively evaluate the optimal loop diuretic use strategy
in patients with AHF. In the pilot study, patients were
enrolled consecutively from the Department of Internal
Medicine, Cardiology Section Center (Siena, Italy), from April
2010 to November 2012.6 In this multicentre study, patients
will be enrolled starting December 2015.
Ethics
The study was approved by the local ethics institutional
board (C.E.A.V.S.E. approved on 19 June 2017) and registered
in Clinicaltrial.gov (identifier number: NCT02638142).
Inclusion criteria
Patients will be enrolled in the study if they are older than
18 years and they meet the diagnostic criteria for AHF,
independently of the systolic function, by exhibiting at least
one symptom at rest among dyspnoea, orthopnoea, periph-
eral oedema, and major fatigue; and at least two clinical signs
including rales, pulmonary congestion on chest X-ray (pulmo-
nary oedema, pulmonary congestion, or pleural effusion),
jugular vein dilatation, and a third heart sound.7 An elevation
in blood BNP ≥ 100 pg/mL is considered supportive for a
diagnosis of AHF (Table 2).
Exclusion criteria
Patients will be excluded from this trial if they received more
than two intravenous doses of furosemide or any continuous
infusion of furosemide up to 1 month before randomization;
if they had end-stage renal disease (eGFR ≤ 15 mL/min/m2)
or need renal replacement therapy (dialysis or ultrafiltration);
or if they had recent myocardial infarction within 30 days of
screening. Patients with a systolic blood pressure <80 mmHg
will also be excluded, as well as patients who have received
recent intravenous iodinated contrast.
Randomization procedure
Patients will be randomized in a 1:1 ratio using a computer-
generated scheme divided into either twice-daily bolus
injections or continuous infusion (mixed as a 1:1 ratio in
5% dextrose in water), for a time period ranging from 72
to 120 h. The cumulative daily dose of intravenous furose-
mide to be given in the initial 12 h will be decided by the
attending physician. Boluses of furosemide will be adminis-
tered in 100 mL of water solution over 1 h. The mean daily
diuretic dosage will be similar in both groups. The specific
doses of furosemide and the use of additional agents to
manage AHF (dopamine, intravenous vasodilators, hyper-
tonic saline infusions for hyponatraemia) will be decided
based on the laboratory (creatinine, electrolytes balance,
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and BNP) and clinical (congestion symptoms and signs)
parameters, with daily dosages adjusted during the infusion
periods (Figure 1). At admission, patients with AHF in both
the intermittent and continuous infusion arms will be
administered with 80 mg/day of intravenous furosemide. If
a patient has a good response, the initial dose will be
continued; if a patient has a poor response, defined as
DE < 0.2 kg/day for 40 mg of furosemide (as mentioned in
our recent paper) and a urine output <1 L/day, the furose-
mide dosage will be doubled (160 mg/day).8 In case of
continued diuretic resistance, defined as a poor response,
the dosage will be raised to 250 mg/day. Therefore, patients
with poor DE will undergo intensification treatment. A low
diuretic dose is defined as a furosemide daily amount
<120 mg/day; conversely, a high dose is defined as a high
loop diuretic dose >120 mg/day (Figure 2).
The diuretic response is defined as the mean daily weight
change from hospital admission to the end of the intravenous
loop diuretics treatment (time period ranging from 72 to
120 h) per 40 mg of daily furosemide dosage. To calculate
DE, we performed the following formula: (Weight
change/days of infusion)/(Mean daily furosemide dosage/
40 mg of furosemide).4,5,8,9
In all patients, before randomization, the renal function
parameters and BNP will be measured. Renal function is
evaluated through serum blood urea nitrogen and serum
creatinine measurement. Moreover, in all patients, eGFR is
calculated by MDRD formula.10 Worsening renal function is
Table 2 Inclusion and exclusion criteria of study protocol
Inclusion criteria Exclusion criteria
Patients >18 years Patients who receive more than two i.v. doses of furosemide
or any continuous infusion of furosemide 1 month
before randomization
Patients with diagnosis of ADHF
Dyspnoea, orthopnoea, peripheral oedema, or major
fatigue and at least two clinical signs including rales,
pulmonary congestion on chest radiography, jugular
vein dilatation, or a third heart sound
Blood BNP > 100 pg/mL
End-stage renal disease or renal replacement therapy
Recent myocardial infarction (within 30 days of screening)
Systolic blood pressure < 80 mmHg
Creatinine levels >4 mg/dL
Patients who receive recent i.v. iodinated contrast
ADHF, acute decompensated heart failure.
Figure 1 Study design describing timing assessment before and after treatment and follow-up evaluation.
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defined as creatinine increase ≥0.3 mg/dL during hospitaliza-
tion or eGFR reduction ≥20% during the same period. Chronic
kidney disease is defined as admission renal dysfunction with
eGFR < 60 mL/min/m2.11 Therefore, all patients will be sub-
mitted to an echocardiography and a chest X-ray to assess
pulmonary congestion. The chest X-ray will also be repeated
prior to treatment suspension to verify the pulmonary
congestion improvement. The subsequent titration of the
furosemide dosage will be guided by a dose-escalation
algorithm based on the patient’s response to the treatment
(DE < 0.2 kg/day for 40 mg of furosemide from the starting
enrolment to the third day or urine output <1000 mL/day)
and signs of decongestion (decreased pulmonary rales,
venous jugular decongestion, lack of additive heart sounds,
and improvement in pulmonary congestion in chest X-ray)
and/or through important changes in renal function such as
a sudden increase of creatinine >0.8 mg/dL compared with
the baseline value or hypokalaemia <3.2 mEq/L.
Additional therapy
Any additional treatment is left to the physician’s discretion.
No thiazide diuretics, nesiritide, or arginine vasopressin
antagonists will be administered during the hospitalization
period. Hypertonic saline solution will be administered to
patients who develop hyponatraemia (serum Na+ values
<130 mEq/L) during treatment with the goal of restoring
plasma sodium values up to 134 mEq/L. For this reason, the
Na+ concentration will be monitored each day during the
infusion period. The hypertonic saline solution consists of
NaCl in 500 mL saline solutions (0.9% of NaCl). Infusion will
be administered at 80 mL/h once a day, depending on the
Na+ levels. The dopamine infusion will be administered to
patients with systolic blood pressure <90 mmHg with the
goal of restoring systolic values up to 100 mmHg, maintaining
diuretic infusion. Inotropic therapy will be stopped when
blood pressure values are sustained at ~105 mmHg during
the subsequent 12 h for four consecutive measurements.
Collection of data
Clinical parameters will be recorded. For the data quality
measurement to be optimized, the following instruction will
be performed: The systolic and diastolic blood pressure will
be calculated using the mean of three consecutive measure-
ments; the heart rate will be monitored and registered by
the investigators involved in the trial. Serial measurement
of the above-cited laboratory parameters will also be
collected. Finally, the clinical status of congestion will be
registered at admission and after treatment. All the collected
Figure 2 Scheme of diuretics dose administration by escalation algorithm based on diuretic response.
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data will be inserted and scheduled in an Excel file, which will
be kept by the principal investigator of the study.
Primary endpoints
Primary endpoints were (i) 180 days cardiac death and
re-hospitalization and (ii) evaluation of adverse events in
relation to the rate of WRF and to congestion signs after
the infusion period during a 6 month follow-up period.
Secondary endpoints
DIUR-AHF has been designed with some in-hospital end-
points: (i) mean paired changes of renal function, of urine
output comparing continuous vs. intermittent administration;
(ii) the evaluation of decongestion, BNP decrease, and WRF
occurrence in relation to DE; (iii) post hoc analysis of WRF,
congestion signs, inotropic infusion, and length of hospital
stay (days) should be performed with respect to the specific
dose groups (high vs. low).
Sample size calculation
The study’s sample size is based on our primary endpoints.
Thus, we considered that the adverse events incidence
(180 days cardiac death or re-hospitalization) is likely to
be 40% in patients undergoing continuous infusion and
25% in patients undergoing intermittent infusion. The
sample size of 240 patients (120 in each arm) might be
helpful in detecting the clinical outcome difference between
the groups (continuous vs. intermittent) with a power of
80%. We assumed no patients would withdraw or be lost
during the hospitalization period. We also consider that
20% of subjects could be lost during follow-up after hospital
discharge.
Statistical plan
All data will be analysed with intention-to-treat principles.
Continuous variables will be expressed as mean ± standard
deviation and will be compared with Student’s t-test
(unpaired and paired as appropriate) for independent groups
if normally distributed; normality will be assessed by the
Kolmogorov–Smirnov test. Analysis of variance will be done
by Levene’s test, and if it is breached, Welch’s correction will
be used. Qualitative variables will be expressed as a percent-
age and will be compared with χ2 test. Data about weight loss
and diuretic response (defined by weight change per 40 mg
of furosemide or equivalent) will be described in quartiles
and will be presented as median (interquartile range). Differ-
ences among diuretic response quartiles will be compared
through analysis of variance when normally distributed or
Kruskal–Wallis test when skewed; Pearson χ2 tests will be
used to compare categorical data. Correlations between DE
and eGFR will be expressed as Pearson’s correlation
coefficient. Cox regression analysis will be used to assess
the independent relationship between the two methods of
furosemide infusion for the outcome of re-hospitalization or
death with adjustment for age, gender, creatinine, eGFR,
and BNP at baseline; the use of hyperosmolar solution;
dopamine infusion; and the development of WRF. Kaplan–
Meier methods will be employed to generate survival plots
that will be compared using a log-rank test for time to first
hospitalization, death, or the composite. All statistical tests
will be two tailed, with P value < 0.05 considered significant.
All the analyses will be performed by using the SPSS 20.0 for
Windows (SPSS Inc., Chicago, IL).
Discussion
Loop diuretics remain the cornerstone of the decongestion
therapy during AHF; however, which is the best modality
administration and daily dosage to improve outcome is not
yet understood: Post hoc analyses have previously shown
that high dosage is associated with a poor prognosis,
although specific analyses on diuretic response and studies
comparing the dose administration during hospitalization
and after discharge have not been done.12,13 Recent guide-
lines recommend the use of these drugs to reduce left
ventricular filling pressure and pulmonary congestion and
avoid idro-saline retention.14 Therapeutic recommendations
focus primarily on symptoms relief since there are no specific
studies evaluating the dose regimen nor modality of adminis-
tration during acute management. Thus, despite the ubiquity
of loop diuretic employments, there is a lack of data
supporting their efficacy and the relative prognostic impact.
In the Acute Decompensated Heart Failure National Registry
(ADHERE) registry, the use of high loop diuretics dosage was
associated with a higher rate of mortality, a prolonged hos-
pital stay, and an increased renal dysfunction.15 The current
trend is also confirmed by other studies.16,17 All together,
these reports suggest an evaluation of potential strategies
for avoiding exposure to high doses for a prolonged period.
Thus, the administration of the lowest possible dosage to
patients with AHF is recommended in order to relieve their
symptoms.17 However, as patients taking the more elevated
regimen are probably the more compromised, the data in-
terpretation needs to be evaluated with caution. Moreover,
several items still remain challenging due to the frequent
exclusion of patients with a more impaired haemodynamic
status and advanced renal dysfunction from major AHF clin-
ical trials.18–20 Therefore, it is not clear whether continuous
infusion is better than intermittent boluses and whether a
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lower dose is better than a higher dose in terms of decon-
gestion efficiency, maintenance of renal filtration function,
and prognosis.21,22 Finally, several concerns regarding
short-term and long-term effects, the consequences of pre-
vious doses taken before hospitalization, and the effective
response during the acute phase remain unknown. A post
hoc analysis showed that the metric responsiveness (calcu-
lated by fluid output produced per 40 mg of furosemide) in-
stead of the diuretic amount has a more prognostic impact.9
These findings seem to be confirmed in two recent trials
employing two new drugs serelaxin and rolofylline, provid-
ing indefinite results.5,23
In this context, the renal function deterioration seems to
have a different significance in relation to different clinical
situations: If it is transient, it could be simply a marker of
effective decongestion; conversely, if it is permanent, it could
due to an increased systemic and renal atherosclerotic bur-
den, a greater neuro-endocrine stimulation, and a reduced
renal blood flow. Loop diuretics, per se, particularly higher
doses, are associated with higher rates of WRF. This phenom-
enon is consistent with an increase of the renin–angiotensin
and sympathetic nervous systems activation. This current
overdrive is mediated by two distinct mechanisms: the inhibi-
tion of sodium chloride intake into the macula densa cells
and the stimulation of prostacyclin that further increases
the secretion of rennin. The indirect effects of loop diuretics
include a reduction in renal blood flow and an enhanced
proximal tubules recovery of sodium in both loop diuretic
doses. Finally, aldosterone works at the collecting duct to
recover the remaining sodium in the urine, while increased
arginine vasopressin can recover as much as 25% of the free
water in urine despite the use of loop diuretics. All of these
factors combine to make the patient prone to adverse
diuretics effects and to increase risk for renal function
deterioration.24 Higher doses of diuretics could be necessary
in severe cases with more impaired renal function, and as
consequence, adverse effects may result from the severity
of the disease.23,25 Therefore, our trial aims to answer
questions regarding the better cumulative daily dose choice
and then to randomize patients in different modalities of
administration.
Expected results
(i) In all arms (continuous vs. intermittent and high vs. low
infusion), some percentage of WRF will occur. (ii) Worsening
renal function occurrence in chronic kidney disease patients
has worse outcome. (iii) Continuous and high dose groups
could reveal a more intensive diuresis and congestion signs
relief with respect to intermittent and low dose groups. (iv)
High dose and poor loop diuretics efficiency should related
to increased diuretic resistance, renal dysfunction occur-
rence, and a greater congestion status. (v) BNP decrease will
be more consistent in patients with greater decongestion. (vi)
Poor diuretic response will be associated with less deconges-
tion and an adverse prognosis. (vii) Outcome will depend on
congestion reduction and renal function deterioration.
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